Compare MHK & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHK | IBRX |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 7.2B |
| IPO Year | 1995 | 2015 |
| Metric | MHK | IBRX |
|---|---|---|
| Price | $107.52 | $7.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $126.10 | $12.57 |
| AVG Volume (30 Days) | 735.1K | ★ 12.5M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 1.90 | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $3.38 | $88.59 |
| Revenue Next Year | $3.09 | $131.15 |
| P/E Ratio | $57.89 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $92.99 | $1.95 |
| 52 Week High | $143.13 | $12.43 |
| Indicator | MHK | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.37 | 45.47 |
| Support Level | $104.49 | $7.77 |
| Resistance Level | $107.98 | $8.54 |
| Average True Range (ATR) | 4.39 | 0.67 |
| MACD | -1.45 | -0.03 |
| Stochastic Oscillator | 8.20 | 30.38 |
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Global Ceramic designs, manufactures, sources, distributes and markets a broad line of ceramic, porcelain and natural stone tile products used for floor and wall applications in residential and commercial channels for both remodeling and new construction. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.